Motixafortide
Also known as: Aphexda, BL-8040, BKT140
A cyclic peptide CXCR4 antagonist used with filgrastim to mobilize stem cells in multiple myeloma. FDA-approved as Aphexda (2023). Hospital medication.
Last updated
Mechanism of Action
Motixafortide is a synthetic cyclic peptide that binds the CXCR4 chemokine receptor with high affinity and slow dissociation. CXCR4 and its ligand CXCL12 (SDF-1) anchor hematopoietic stem cells in the bone marrow; blocking this interaction releases stem cells into the blood. Combined with G-CSF (filgrastim), it increases the number of CD34+ cells that can be collected by apheresis for autologous transplant.
- Half-life
- ~2 hours
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Stem cell mobilization before autologous transplant in multiple myeloma
- More patients reached collection targets in fewer apheresis sessions (GENESIS)
- Used together with filgrastim
Potential Side Effects
- Injection-site reactions (pain, redness, itching)
- Pruritus, flushing and back pain
- Anaphylactic shock and hypersensitivity reactions (label warning; premedication used)
Common Dosing
Aphexda is given by clinicians as a single weight-based subcutaneous injection after several days of filgrastim, timed before apheresis, with premedication to reduce reactions; a second dose may be given if needed. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- History of serious hypersensitivity to motixafortide
- Not for mobilizing leukemic cells (label limitation)
No documented stacking partners for Motixafortide yet.